Simulations Plus, Inc. SLP 深 滬
等待開盤 06-26 09:30:00 美东时间
18.15
-0.020
-0.11%
華盛通- 最 高18.195
- 今 開18.19
- 成交量 42.00万股
- 最 低 18.15
- 昨 收 18.17
- 總市值 3.67亿
- 52周最高 21.01
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 11.09
- 委 比 87.71%
- 總股本 2021.64万
- 歷史最高 90.08
- 量 比 0.81
- 振 幅 0.25%
- 歷史最低 0.47
- 每 手 1
- 風險率 2.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多William Blair Downgrades Simulations Plus to Market Perform
William Blair analyst Max Smock downgrades Simulations Plus (NASDAQ:SLP) from Outperform to Market Perform.
06-17 20:40
Simulations Plus, One Stop Systems, Space Exploration Technologies And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Tuesday. Shares of Simulations Plus Inc (NASDAQ:SLP) rose sharply as the company agreed to be acquired by Altaris for approximately $375 million. Simulations Plus shares jumped 12.4% to $18.40 on Tuesday. Here are some ot...
06-16 22:08
Simulations Plus Partners With Nvidia Over GPU-Accelerated Simulation, AI-Assisted Workflows For Computationally Intensive Modeling Applications Within The Drug Development Lifecycle
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the launch of a
05-06 19:56
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.
04-23 03:23
Simulations Plus Partners With Lonza Group, FDA To Develop, Validate Framework For Amorphous SOLID Dispersion Drug Products
Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded research
04-21 20:01
美股大行评级 | 大砍54%！大摩下调Robinhood 目标价从147降至95美元；星座品牌酒业(STZ)获8家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9.5美元升至9.75美元；Citizens：维持戴夫"跑赢大市"评级，目标价从310美元升至335美元
04-13 14:07
电话会总结 ｜ Simulations Plus(SLP)2026财年Q2业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Simulations Plus业绩会实录，以下是业绩回顾摘要： ## 1. 财务业绩 **第二季度总体表现：** - 总营收达到2,430万美元，同比增长8% - 软件业务营收增长9%，占总营收的60% - 服务业务营收增长8%，占总营收的40% - 调整后EBITDA为870万美元，利润率达36% - 调整后稀释每股收益为0.35美元 **分业务线表现：** - 发现业务营收季度增长19%，过去12个月增长6%，占软件营收的19% - 开发业务营收季度增长12%，过去12个月增长3%，占软件营收的78% - 临床运营业务营收季度下降54%，仅
04-11 12:33
What's Going On With Simulations Plus Stock Friday?
Simulations Plus beats Q2 estimates, trims fiscal 2026 earnings outlook, and keeps sales guidance intact on favorable market conditions.
04-11 01:42
Simulations Plus shares are trading higher after the company reported better-than-expected Q2 financial results.
Simulations Plus shares are trading higher after the company reported better-th...
04-10 04:19
